Arcadia Biosciences Q2 Loss Widens to $6.3M, but Zola Sales Inflect with July Revenue Topping $740K
RKDA is trading near its 52-week low of $0.497 (15% above the low) on light trading volume (0.2× avg).
Summary
Arcadia Biosciences reported a wider Q2 net loss of $6.27 million, but highlighted a sharp inflection in Zola sales with July revenue exceeding $740,000 and new product launches planned for Q4 2026 and H1 2027.
Key Events · Earnings and Guidance · RKDA
-
Q2 Net Loss Widens to $6.27M
Net loss attributable to common stockholders was $6.27 million, or $2.09 per share, compared to $4.46 million, or $3.26 per share, in Q2 2025. The loss included a $5.4 million valuation loss on the June 2026 PIPE and a $2.8 million unrealized loss on Above Food stock.
-
Zola Sales Inflect in July
July monthly Zola sales topped $740,000, more than half of the entire Q2 revenue of $1.44 million, and exceeded $1 million through the first week of August. Management attributed the inflection to resolving low inventory and shipping delays.
-
Cash Position and Burn Improve
The company ended Q2 with $4.2 million in cash after the $4 million private placement. Net cash used in operating activities was only $319,000 in Q2, and SG&A declined by $1.0 million year-over-year to an all-time low.
-
New Product Launches Planned
Arcadia will launch a 1-liter espresso in Q4 2026 with pre-launch commitments from its two largest customers, and plans to launch three additional new products in the first half of 2027.
Analysis · RKDA · Energy & Transportation
The Q2 net loss widened to $6.27 million from $4.46 million a year ago, driven by a $5.4 million valuation loss on the June PIPE and a $2.8 million unrealized loss on Above Food stock. However, the company ended the quarter with $4.2 million in cash after the $4 million private placement, and operating cash burn was only $319,000. Management highlighted that Zola sales reached an inflection point: July sales exceeded $740,000, more than half of the entire second quarter's revenue, and surpassed $1 million through the first week of August. The company also announced a Q4 2026 launch of a 1-liter espresso with pre-launch commitments from its two largest customers, plus three additional products planned for the first half of 2027. This is a mixed picture: severe accounting losses and going-concern risk persist, but the underlying operating business is showing signs of stabilization and growth.
At the time of this filing, RKDA was trading at $0.57 on NASDAQ in the Energy & Transportation sector, with a market capitalization of approximately $1.4M. The 52-week trading range was $0.50 to $6.71. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.